Lanréotide Viatris Lp (Lanreotide)

Lanreotide mimics the natural hormone somatostatin and binds to somatostatin receptors SSTR2 and SSTR5. This binding blocks the release of several hormones, including growth hormone, insulin, and glucagon, and reduces cell proliferation in certain neuroendocrine tumors.

The specific dose and dosing interval are determined by the prescribing clinician based on the individual’s condition, disease severity, and response to therapy. Lanréotide is administered as a subcutaneous injection, and the prescriber will set the appropriate regimen.

The safety of lanreotide in pregnancy and lactation has not been established. It should only be used if the potential benefit justifies the potential risk to the fetus or infant, and this decision must be made by a qualified healthcare professional.

To place an order, submit an enquiry on the product page at gnhindia.com, specifying the required quantity. GNH India works with hospitals, pharmacies, and procurement teams worldwide, verifies trade or institutional credentials, and then provides pricing, availability, shipping details (including cold‑chain if needed), and import documentation.

Lanreotide and other analogs such as octreotide share the same mechanism of receptor activation, but lanreotide is formulated as a long‑acting depot that can be administered less frequently, often every 4‑8 weeks, whereas octreotide may require more frequent dosing.

Lanréotide Viatris Lp should be stored in a refrigerator at 2‑8 °C. Keep the vial in its original packaging, protect it from light, and avoid freezing or shaking the suspension before use.

The medication is given as a subcutaneous injection, typically into the abdomen or thigh. A healthcare professional prepares the dose from the injectable suspension and administers it according to the schedule set by the prescriber.

Serious risks include acute pancreatitis, severe hyperglycemia that may require medical intervention, and rare allergic reactions such as anaphylaxis. Patients should be monitored for signs of these conditions and instructed to seek immediate medical care if they occur.

Lanréotide is contraindicated in patients with known hypersensitivity to lanreotide or any of the formulation excipients. Caution is also advised for individuals with uncontrolled diabetes, severe hepatic or renal impairment, or active gallbladder disease, and the decision to treat should be made by a qualified clinician.